SCHEMBL4923356

SCHEMBL4923356

CC(C)COc1ccc(Cl)cc1Cc1ccc(C(=O)Nc2c(F)cccc2F)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 9/20 0.65
GAA P10253 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 1/20 0.50
S1PR4 O95977 1/20 0.48
NPSR1 Q6W5P4 3/20 0.46
LMNA P02545 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
HTT P42858 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 2/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924041 0.91 PTGER1 (0.53) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4918860 0.88 PDE4D (0.51) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4923036 0.88 PTGER1 (0.61) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4923904 0.87 PTGER1 (0.66) PTGER1GAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL4925046 0.87 SMN1; SMN2 (0.56) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4914154 0.86 GAA (0.58) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4924893 0.86 GAA (0.55) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4926019 0.86 PTGER1 (0.67) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4927580 0.86 PTGER1 (0.56) PTGER1GAASMN1; SMN2ALDH1A1S1PR4
SCHEMBL4925217 0.86 PTGER1 (0.59) PTGER1GAASMN1; SMN2ALDH1A1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists PTGER1, PTGER2, PTGER3 PTGER1 1/4885GAA 4729/4885SMN1; SMN2 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.